Laronde’s Endless RNA (eRNA) is a versatile synthetic RNA platform designed to instruct cells to express a desired therapeutic protein inside the body. Because eRNA has no free ends, it is not recognized by the immune system and is stable, enabling a longer duration of protein expression than linear RNA. “We’re talking about weeks to months,” Laronde CEO Diego Miralles, MD, told GEN Edge
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post Circle Line: Laronde’s “Endless” RNA Draws $440M from Investors appeared first on GEN – Genetic Engineering and Biotechnology News.
